Skip to main content

Table 1 Included studies and baseline characteristics of the patients

From: Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome

Study code a

Publication, first author, study acronym

Year

Study design

Indication

Number of patients

Male gender (%)

Mean age (years)

Treatment duration (months)

Follow-up (months)

01

Finkelstein Y. et al. [19]

2002

Multicenter, randomized, double blind

PPS prevention

111

73

64.0

1

3

02

Imazio M. et al., CORE [20]

2005

Single center, randomized, open label

PER recurrence

84

35

53.8

6

20

03

Imazio M. et al., COPE [21]

2005

Multicenter, randomized, open label

PER first episode

120

45

56.9

3

24

04

Imazio M. et al., COPPS [22]

2010

Multicenter, randomized, double blind

PPS prevention

360

66

65.7

1

19

05

Imazio M. et al., CORP [23]

2011

Multicenter, randomized, double blind

PER recurrence

120

52.5

47.6

6

18

06

Imazio M. et al., ICAP [24]

2013

Multicenter, randomized, double blind

PER first episode

240

60

52.1

3

22

07

Imazio M. et al., COPPS-2 (11)

2014

Multicenter, randomized, double blind

PPS prevention

360

69

67.5

1

3,1

08

Imazio M. et al., CORP-2 (10)

2014

Multicenter, randomized, double blind

PER recurrence

240

50

48.8

6

20

09

Meurin P. et al., POPE-2 (21)

2015

Multicenter, randomized, double blind

PE post heart surgery

197

86

64.5

0.5

6

10

Izadi Amoli A. et al., [18]

2015

Single center, randomized, triple blind

PE post heart surgery

149

60

57.4

0.5

1

  1. astudy code of the publications included in the meta-analysis
  2. PE pericardial effusion, PER pericarditis, PPS post-pericardiotomy syndrome